key: cord-0864395-v65rye5w
authors: Jeewandara, Chandima; Jayathilaka, Deshni; Gomes, Laksiri; Wijewickrama, Ananda; Narangoda, Eranga; Idampitiya, Damayanthi; Guruge, Dinuka; Wijayamuni, Ruwan; Manilgama, Suranga; Ogg, Graham S.; Tan, Chee Wah; Wang, Lin-Fa; Malavige, Gathsaurie Neelika
title: SARS-CoV-2 neutralizing antibodies in patients with varying severity of acute COVID-19 illness
date: 2021-01-21
journal: Sci Rep
DOI: 10.1038/s41598-021-81629-2
sha: 1399c7c3deb63db3ec7ddac3a43f362b316d94a7
doc_id: 864395
cord_uid: v65rye5w

In order to support vaccine development, and to aid convalescent plasma therapy, it would be important to understand the kinetics, timing and persistence of SARS-CoV-2 neutralizing antibodies (NAbs), and their association with clinical disease severity. Therefore, we used a surrogate viral neutralization test to evaluate their levels in patients with varying severity of illness, in those with prolonged shedding and those with mild/asymptomatic illness at various time points. Patients with severe or moderate COVID-19 illness had earlier appearance of NAbs at higher levels compared to those with mild or asymptomatic illness. Furthermore, those who had prolonged shedding of the virus, had NAbs appearing faster and at higher levels than those who cleared the virus earlier. During the first week of illness the NAb levels of those with mild illness was significantly less (p = 0.01), compared to those with moderate and severe illness. At the end of 4 weeks (28 days), although 89% had NAbs, 38/76 (50%) in those with > 90 days had a negative result for the presence of NAbs. The Ab levels significantly declined during convalescence (> 90 days since onset of illness), compared to 4 to 8 weeks since onset of illness. Our data show that high levels of NAbs during early illness associated with clinical disease severity and that these antibodies declined in 50% of individuals after 3 months since onset of illness.

www.nature.com/scientificreports/ more for the total IgG antibodies than the NAbs, suggesting that NAbs that are needed for subsequent protection could be long lasting. Following MERS-CoV and SARS-CoV infection, functional NAbs were shown to persist for over 1 year 11 and up to at least 17 years 12 , although they were undetectable in significant proportion of individuals by 30 to 34 months 13, 14 . Antibody responses to other seasonal coronaviruses also have shown to be short-lived and that individuals could be infected with coronaviruses such as NL63 within a 6 month period 15 . Therefore, in order to develop effective vaccines, it would be important to answer key questions such as if the appearance of NAbs led to less severe disease, stopped virus shedding and their persistence. In this study, we initially investigated the kinetics of SARS-CoV-2 specific NAbs in a cohort of patients with varying severity of illness, then proceeded to further characterize the responses at different time points in relation to clinical disease severity and also investigate their persistence of NAbs after 90 days since onset of illness.

Determining specificity of the sVNT in measuring SARS-CoV-2 NAbs in the Sri Lankan population. In order to determine the specificity of the sVNT in Sri Lankan individuals, we initially assessed the % of inhibition in 81 serum samples obtained from individuals who presented with a febrile illness to the outpatient department of the National Institute of Infectious Diseases (NIID), Sri Lanka in 2018. All these individuals had a % of inhibition less than the cut of value of 25%. We then assessed the specificity of the assay in 285 non-exposed individuals recruited from the Colombo Municipality area during the month of April. The percentage of inhibition in this population was also less than the cut-off value. Therefore, the specificity of this assay was found to be 100% as previously described 16 .

Longitudinal changes in NAbs in patients with varying severity of clinical disease. In order to determine the longitudinal changes of SARS-CoV-2 NAbs in patients with varying clinical disease severity, we assessed their levels in those with severe (n = 6), moderate (n = 5) and mild/asymptomatic illness (n = 13) and also those who had mild illness but with prolonged shedding of the virus (n = 21). Those who shed the virus for over 25 days were considered as those with prolonged shedding. Of the 21 individuals with prolonged shedding, there were 10 individuals who had shedding for over 50 days. The patterns of virus shedding in those with mild but prolonged illness is shown in Fig. 1 .

In patients with severe and moderate illness and in those with prolonged shedding, blood samples were obtained during the first week, second week and at the time when they were discharged from the hospital (4 to 6 weeks since onset illness). As those with mild illness were discharged from hospital during the second week of illness, the first two blood samples (1st week and 2nd week) were obtained while in hospital and again their third blood sample was obtained after discharging from the hospital, while they were at home (4 to 6 weeks since onset of illness).

In the longitudinal analysis of NAbs, they appeared earlier and faster, at higher levels in those who had severe and moderate pneumonia, followed by those who had prolonged shedding, while they appeared later, at lower levels in those who had mild/asymptomatic disease ( Fig. 2A ). 4/13 individuals with mild illness had no detectable NAbs even 40 days since onset of illness, whereas only 1/21 individuals with prolonged shedding had NAbs below detection level (< 25% of inhibition).

The timing of the appearance of NAbs and their levels in relation to clinical disease severity. In order to further evaluate the appearance and the quantity of NAbs in relation to clinical disease severity, www.nature.com/scientificreports/ we assessed antibodies in blood samples at different time points from patients with severe pneumonia (n = 10), moderate illness (n = 19), mild illness (n = 150) and prolonged shedding (n = 82). The NAbs levels were determined in this larger cohort of individuals during the first 3 weeks and during week 4 to 8 of illness. Again, those with moderate and severe illness had higher NAbs levels (median 63. 16 and 48.9% of inhibition) during the 1st week, and in all subsequent time points compared to those with mild and prolonged shedding ( Fig. 2A) . During the first week of illness the NAb levels of those with mild/prolonged illness (median = 10.3, IQR 3.5 to 18.2% of inhibition) was significantly less (p = 0.01), compared to those with moderate and severe illness (median 63.2, IQR 9.9 to 95.2% of inhibition). There was no difference in the NAb levels during the first week of illness in those with mild illness and mild but prolonged illness (p = 0.71). After the 3rd week (4th to 8th week), although all patients with severe, moderate and prolonged shedding had a positive test result, 23/69 (33.3%) of those with mild/asymptomatic illness were negative (% of inhibition < 25). Those with prolonged shedding, who had mild or asymptomatic illness had significantly higher (p < 0.0001) NAb levels (median 76.4%, IQR 52.32 to 89.5% of inhibition) than those with mild/asymptomatic illness (median 47.9%, IQR 18.9 to 77.1% of inhibition) during week 4 to 8. This data further reinforces the longitudinal analysis of NAbs as shown in Fig. 2B .

We then proceeded to assess the detection of NAbs at various time points in illness, irrespective of clinical disease severity and also to assess if NAbs persisted over 90 days since onset of illness. NAbs were measured by the sVTN on day 14 to 21 (n = 98), day 22 to 28 (n = 100), day 29 to 36 (n = 132), day 37 to 42 (n = 32), day 43 to 49 (n = 16), day 50 to 70 (n = 29) and > 90 days (n = 76). The positivity rates during day 14 to 21 was 79.8%, day 22 to 28 was 89%, day . SARS-CoV-2 NAbs were measured in those with severe (n = 6), moderate (n = 5) and mild/ asymptomatic illness (n = 13) and also those who had mild illness but with prolonged shedding of the virus (n = 21) (A). In order to assess the timing of the NAb responses at different time point, these antibodies were measured in patients with severe pneumonia (n = 10), moderate illness (n = 19), mild illness (n = 150) and prolonged shedding (n = 82). The NAbs levels were determined in this larger cohort of individuals during the first 3 weeks and during week 4 to 8 of illness (B). The black dotted line indicates the cut-off value of a positive result. 

In this study, we show that the early appearance of SARS-CoV-2 NAbs at high levels was not associated with milder disease nor with early clearance of the virus. Early appearance of NAbs has previously shown to occur in those with severe disease compared to those with mild illness 17 . It was recently shown that a high frequency of extrafollicular B cells development is seen in COVID-19, which correlated with disease severity. These extrafollicular B cells were responsible for development of development of SARS-CoV-2 specific neutralizing antibodies, very early during illness, which was shown to associate with severe disease 18 . In addition to production of NAbs by extrafollicular B cells, the early appearance of NAbs in patients with more severe disease could be due to the boosting of NAbs specific to previous coronaviruses. Therefore, early appearance of such cross-reactive antibody responses could have a potential to cause severe illness by antibody dependent enhancement 19 . Higher initial viral loads were associated with progression to more severe disease in SARS 20, 21 . Therefore, higher viral loads could drive a more robust NAb response. However, infants who were symptomatic had higher nasopharyngeal viral loads, but less severe illness compared to older children with more severe illness 22 , suggesting that higher viral loads were not necessarily associated with more severe illness. www.nature.com/scientificreports/ It was seen that by the end of 4 weeks, 11% of individuals did not have adequate quantities of NAbs. Since the onset of the outbreak, due to the lack of specific treatment options, convalescent plasma of recovered patients with COVID-19 has been used to treat patients with moderate or severe COVID-19 illness 23, 24 . The FDA, USA has issued an emergency use authorization for the use of convalescent plasma as it was believed that it may be effective 23 . Although randomized clinical trials have not been conducted to determine the efficacy of this treatment, as use of convalescent plasma depends on the presence of high levels of NAbs, it is recommended to test the presence of high titres, before selection of potential donors 25, 26 .

The relationship between the appearance of NAb with duration of virus shedding has not been previously studied. Surprisingly, those who had prolonged shedding had higher levels of NAbs than those who cleared the virus, and the NAbs appeared in such prolonged shedders earlier than in those who cleared the virus earlier. In Sri Lanka, until recently, patients with COVID-19 were only discharged from hospital if they had 2 negative PCRs, 24 h apart. Therefore, despite these prolonged shedders developing antibodies earlier than those who cleared the virus, and at higher titres, they still continued to shed the virus. Although the majority of such prolonged shedders had lower viral titires (Ct values > 30), some individuals still had higher viral loads even after 30 days of illness. As many other countries do not keep patients in hospital until they become PCR negative, the relationship between early appearance of NAbs and yet persistence has not been documented previously and questions the role of NAb alone in viral clearance.

Although NAbs are thought to associate with protection, this has not been the case with infections such as dengue, which induce cross reactive antibodies as seen between different coronaviruses. Those with high NAbs for a particular dengue virus serotype were found to get re-infected with the same serotype 27 . In addition, the kinetics of NAbs levels in those with varying severity of dengue, was remarkably different based on the infecting dengue virus serotype 28 . Therefore, it is crucial to carry out further studies to identify the protective antibody responses for the SARS-CoV-2, their persistence and their ability to prevent re-infection. As it is clearly evident that patients with COVID-19 had varying levels of NAbs at recovery, it would be important to assess their NAbs by using a simple assay such as this sVNT, for selection of suitable donors.

Although the majority of individuals appeared to be antibody positive by end of week 5, the positivity rates declined thereafter. The decline in NAb antibodies in COVID-19 patients has been documented in recent reports 17 , which has implications in providing long lasting immunity through vaccination. Although we only tested NAbs in a small cohort of individuals with more 90 days since onset of illness, none of those with mild/ asymptomatic illness had NAb above the cut-off value. Further studies are required to determine if such individuals have memory B cell responses and functional Nab even at low levels that would prevent re-infection.

In summary, we show that the early appearance of SARS-CoV-2 NAbs at high levels was not associated with milder disease nor with early clearance of the virus and that NAbs did not persist in those with mild/asymptomatic illness.

Patients. Patients were recruited from the National Institute of Infectious Diseases (NIID), Sri Lanka and the Theldeniya Covid-19 Management Centre in Kandy. The patients were followed throughout their illness while they were in hospital and the severity grading was based on the worst severity while in hospital. Clinical disease severity was classified as mild, moderate and severe according to the WHO guidance of COVID-19 disease severity 29 . Accordingly, those who had a confirmed symptomatic SARS-CoV-2 infection with either fever, cough, fatigue, anorexia, myalgia and shortness of breath and with non-specific symptoms such as sore throat, headache and diarrhoea, but with no evidence of hypoxia or pneumonia were classified as having mild illness. Those with clinical signs of pneumonia with a respiratory rate of > 30 breaths/min, or with SpO 2 < 90% on room air were considered as having severe pneumonia 29 . Those with clinical and radiological signs of pneumonia, but who did not fulfill the criteria of severe disease were classified as having moderate illness. The clinical data of all patients were retrieved from their clinical records within one week after discharge from hospital and entered to case record forms. Their clinical records contained all clinical details including clinical features, radiological investigation details, laboratory investigations and their results on different days. Although many patients with mild illness recovered from illness during the first week since onset of symptoms, they had to be hospitalized until they had two negative PCRs, 24 h apart. Until early July 2020, COVID-19 patients in Sri Lanka were only discharged from hospital when they had two negative PCRs, 24 h apart, which led to many patients being hospitalized for prolonged periods due to continued shedding of the virus 30 . Therefore, for the purpose of the evolution of the antibody response, we assessed presence of Nabs since onset of illness, rather than correlating responses with the duration of illness.

In order to determine the changes of Nabs with varying clinical disease severity, we assessed their levels in those with severe (n = 6), moderate (n = 5) and mild/asymptomatic illness (n = 13) and also those who had mild illness but with prolonged shedding of the virus (n = 21). Blood samples were obtained during the first week, second week and when they were discharged from hospital (4 to 6 weeks since onset illness) in all patients except the two patients who succumbed to their illness during the end of the second week since onset of illness. The duration of illness was defined from the day or onset of symptoms and not the day or PCR positivity or admission to hospital.

The median duration of virus shedding in this whole cohort was 25 days (IQR 15 to 38 days) and therefore, those who had virus shedding for over 25 days and hospitalized for over 25 days were considered to have prolonged shedding of the virus. www.nature.com/scientificreports/ The timing of the appearance of NAbs and their levels in relation to clinical disease severity. Since only a limited number of patients were included in the longitudinal analysis of the NAbs in patients with varying severity of illness (n = 36), we recruited additional patients to determine the appearance of NAbs at different time points. For this purpose, we assessed antibodies in blood samples at different time points from patients with severe pneumonia (n = 10), moderate illness (n = 19), mild illness (n = 150) and prolonged shedding (n = 82). The NAbs levels were determined in this larger cohort of individuals during the first 3 weeks and during week 4 to 8 of illness. The duration of illness was defined from the day or onset of symptoms and not the day or PCR positivity or admission to hospital. In the patients who were completely asymptomatic, the day of illness was defined as the day of PCR positivity. Determining the specificity of the sVNT. Sera from 81 patients who presented to the outpatient department of the NIID, in 2018 for treatment for a febrile illness were used to determine the specificity of the assay. Informed consent was obtained from patients with COVID-19 and those recruited from the outpatient department at NIID. 285 healthy individuals who were not exposed to individuals with COVID-19 were recruited from the Colombo Municipality Council area following informed written consent for further validation of the specificity of this assay.

Sciences, University of Sri Jayewardenepura. The study on humans were carried out in accordance with relevant guidelines and regulations (the Declaration of Helsinki). Assay to measure NAb. As measuring SARS-CoV-2 NAbs would require a BSL-3 facility and limit the number of samples that can be assessed, we adopted a recently developed surrogate virus neutralization test (sVNT) 16 , which measures the percentage of inhibition of binding of the RBD of the S protein to recombinant ACE2 (Genscript Biotech, USA). Inhibition percentage ≥ 25% in a sample was considered as positive for NAbs.

Statistical analysis. Data was analyzed by GraphPad Prism 8 version 8.4.2. The differences in NAb titres in patients at different time points with different disease severity was assessed using the two tailed Mann-Whitney U-test. The differences in NAb titres in those with mild/mild but prolonged shedding with those of severe or moderately severe illness was assessed again using the two tailed Mann-Whitney U-test. In order to determine the differences in the NAb titres in the same individual during early illness (week 4 to 8 since onset of illness, time point A), and convalescence (> 90 days of illness, time point B), we used the paired t test.

Draft landscape of COVID-19 candidate vaccines

Completion of clinical trials in light of COVID-19

Clinical trials of monoclonal antibodies to prevent COVID-19 now enrolling

Treatment of COVID-19 with convalescent plasma: Lessons from past coronavirus outbreaks

Use of convalescent plasma therapy in SARS patients in Hong Kong

Convalescent plasma transfusion for the treatment of COVID-19: Systematic review

Towards characterized convalescent plasma for COVID-19: The dose matters

Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

MERS-CoV antibody responses 1 year after symptom onset, South Korea

Lack of cross-neutralization by SARS patient sera towards SARS-CoV-2

Persistence of antibodies against Middle East respiratory syndrome coronavirus

Disappearance of antibodies to SARS-associated coronavirus after recovery

Human coronavirus NL63 molecular epidemiology and evolutionary patterns in rural coastal Kenya

A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike proteinprotein interaction

Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection

Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19

Antibody dependent enhancement due to original antigenic sin and the development of SARS

Initial viral load and the outcomes of SARS

Viral loads in clinical specimens and SARS manifestations

Symptomatic infants have higher nasopharyngeal SARS-CoV-2 viral loads but less severe disease than older children

Convalescent plasma for covid-19

Convalescent plasma treatment of severe COVID-19: A propensity score-matched control study

Convalescent plasma therapy for COVID-19: State of the art

Convalescent plasma treatment for SARS-CoV-2 infection: Analysis of the first 436 donors in England

Homotypic dengue virus reinfections in Nicaraguan children

Phenotype and functionality of follicular helper T cells in patients with acute dengue infection

Clinical Management of Severe Acute Respiratory Infection when Novel Coronavirus (2019-nCoV) Infection is Suspected: Interim Guidance (WHO

Coronavirus disease 2019

We are grateful to the Centre for Dengue Research, UK Medical Research Council and the Foreign and Commonwealth Office for support. Serology work in the Wang Lab at Duke-NUS is supported by Singapore National Medical Research Council (STPRG-FY19-001 and COVID19RF-003).

The authors declare no competing interests.

Correspondence and requests for materials should be addressed to G.N.M.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.